ArticleLeukemia research reports2026

Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study.

Sinem Namdaroğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.